Fundraising FoxCytosolix
Tolland, US · Delaware corporation · 4 known investors
Find your way into Cytosolix
Sign up to see every warm intro you have to Cytosolix
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cytosolix team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cytosolix uses its Tumor Activated Permeability (TAP) platform to redesign small molecule oncology drugs into weakly-acidic derivatives that exploit tumor acidity to selectively target and accumulate in solid tumors while sparing healthy tissue. Based on research from Yale University, its pipeline includes an androgen receptor inhibitor for early-stage prostate cancer and additional inhibitors for breast and other cancers.
Founders & leadership
Board
Investors · 4
How we know: Backed's portfolio page · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: BlueYard Capital's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$6.6M disclosed across 1 round · 2023
▶$6.6MraisedJun 2023 · 12 investors · BiotechnologyRule 506(b)
- Jason WhitmireDirector
- John DeaconExecutive Officer, Director
- Colin J. FosterExecutive Officer, Director
- Alex BrunickiDirector
- Offering amount
- $6.6M
- Amount sold
- $6.6M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Cytosolix do?
- Cytosolix uses its Tumor Activated Permeability (TAP) platform to redesign small molecule oncology drugs into weakly-acidic derivatives that exploit tumor acidity to selectively target and accumulate in solid tumors while sparing healthy tissue. Based on research from Yale University, its pipeline includes an androgen receptor inhibitor for early-stage prostate cancer and additional inhibitors for breast and other cancers.
- Who are Cytosolix's investors?
- Cytosolix's investors include Backed, BlueYard Capital, Connecticut Innovations, BY Capital GmbH Co. KG.
- How much funding has Cytosolix raised?
- Cytosolix has disclosed $6.6M raised across 1 round.
- Where is Cytosolix headquartered?
- Cytosolix is headquartered in Tolland, US.